Your AI-Trained Oncology Knowledge Connection!

Liver Cancer

Latest News

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer

July 13th 2025

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.

HAIC Regimen Yields Long-Term Survival in Unresectable HCC

By Russ Conroy

July 8th 2025

SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.

FDA Approves SIR-Sphere Y-90 in HCC

By Ariana Pelosci

July 7th 2025

Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.

Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC

By Roman Fabbricatore

May 30th 2025

$Ten-fraction image-guided hypofractionated radiation therapy could be a feasible treatment option for portal vein tumor thrombosis in patients with HCC.$

Hypofractionated RT Shows Portal Vein Tumor Thrombosis Control, OS in HCC

By Roman Fabbricatore

April 29th 2025

Latest CME Events & Activities

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Oncology Town Hall™ 2025 ESMO-GI Congress Highlights: The Latest Data on Immune-Based Strategies Across Hepato...

July 15, 2025

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?